Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dyadic Nederland, a subsdiary of Dyadic International, has signed a research pact with the vaccines division of sanofi-aventis Group Sanofi Pasteur and EnGen Bio.
Subscribe to our email newsletter
As per the terms of the agreement, Sanofi Pasteur will fund collaborative research at Dyadic Netherland’s R&D facility in Wageningen, which will utilize Dyadic’s proprietary and patented C1 Platform Technology for certain vaccine applications.
The research is expected to be organized under the guidance of Dyadic Netherland general manager Wim van der Wilden with EnGen Bio president and CEO Mark Alfenito.
Dyadic president and CEO Mark Emalfarb said they are very pleased to have the opportunity to work with Sanofi Pasteur and EnGen Bio to further demonstrate the utility of their C1 technology for certain vaccine applications.